Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial-Reference-Cited by-同舟云学术

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Published:2014-02 Issue:2 Volume:15 Page:143-155
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Reck Martin,Kaiser Rolf,Mellemgaard Anders,Douillard Jean-Yves,Orlov Sergey,Krzakowski Maciej,von Pawel Joachim,Gottfried Maya,Bondarenko Igor,Liao Meilin,Gann Claudia-Nanette,Barrueco José,Gaschler-Markefski Birgit,Novello Silvia

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11;Ferlay,2013

2. Non-small cell lung cancer;Ettinger;J Nal Compr Canc Netw,2012

3. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line;Leighl;Curr Oncol,2012

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

Cited by 825 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer;Cancer Drug Resistance;2024-09-10

2. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study;Journal of Clinical Oncology;2024-09-09

3. Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system;Frontiers in Pharmacology;2024-09-02

4. Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?;European Journal of Cancer;2024-09

5. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial;Journal of Clinical Oncology;2024-09-01